Sister to Sister

(HealthDay News) -- A bit of preparation can make bath time less stressful for parents and safer for baby.

(HealthDay News) -- Cirrhosis is the medical term used to describe the slow deterioration of the liver as a result of chronic injury to the organ.

THURSDAY, Sept. 2 (HealthDay News) -- Many Americans have skewed perceptions when it comes to their weight, often believing they are lighter than they actually are, even when the scales are shouting otherwise, a new poll finds.

THURSDAY, Sept. 2 (HealthDay News) -- Military veterans with post-traumatic stress disorder, or PTSD, are more likely to develop dementia than those without the disorder, according to researchers at a Veterans Affairs medical center in Texas.

A study funded by Abbott Laboratories offered more detailed evidence that its weight-loss drug Meridia increases heart risks, prompting renewed calls by consumer advocates and others to pull the drug from the market.

While staying mentally active in old age has been linked to a delayed onset of dementia, seniors who engage in such brain "exercise" may actually have a faster rate of decline once Alzheimer's is diagnosed, researchers reported Wedne...

The chief of the UNAIDS agency said Thursday that global contributions to fighting the disease are dropping off for the first time in 15 years amid tough economic times.

Allergan Inc., the maker of wrinkle-smoothing Botox, has agreed to pay $600 million to settle a yearslong federal investigation into its marketing of the top-selling, botulin-based drug.

WEDNESDAY, Sept. 1 (HealthDay News) -- Human immune systems are much more alike than previously believed, a finding that may lead to new ways to detect, diagnose and treat cancer and autoimmune diseases, say U.S. researchers.

Teenagers who sleep less than eight hours a night on weeknights eat more fatty foods and snacks than those who get more than eight hours of sleep a night, U.S. researchers said on Wednesday.

Contrary to international guidelines, sugar given to newborn babies does not ease pain, according to a study published on Thursday by The Lancet.

Scientists are reporting a major advance in diagnosing tuberculosis: A new test can reveal in less than two hours, with very high accuracy, whether someone has the disease and if it's resistant to the main drug for treating it.

Editors of a top medical journal call Meridia "another flawed diet pill" and question whether it should stay on the market as a study shows it raises the risk of heart attack and stroke in people with heart problems.

One of the country's leading medical journals is looking for a new editor.

WEDNESDAY, Sept. 1 (HealthDay News) -- A new study is linking the popular weight loss drug Meridia to an increased risk of non-fatal heart attacks and stroke, although taking the drug did not seem to up the risk of death in patients with a history of heart problems.

The finding is stirring mixed reactions from experts.

According to the authors of the trial, which was funded by Meridia's maker, Abbott, the findings are generally in line with what has been known about the drug and shouldn't change how it is used.

"The only time you've got an increase in heart attacks or strokes were in those patients who had had previous heart disease or strokes, in other words, the people who . . . should never have received the drug in the first place," said Dr. Philip T. James, a professor at the London School of Hygiene and Tropical Medicine in England, and first author on the paper, which appears in the Sept. 2 issue of the New England Journal of Medicine.

Since January, Meridia (sibutramine), has carried a label warning that it should not be used by people with preexisting heart disease, so "the current prescription is entirely appropriate," James said.

However, not everyone agrees. The U.S. Food and Drug Administration is slated to meet in September to decide if more regulatory action -- perhaps a tougher "black-box" warning or even removing Meridia from the market -- should be taken.

According to Dr. Greg Curfman, executive editor of the NEJM and co-author of an accompanying editorial, the FDA's January warning was based on preliminary information only. The new study results represent the first hard data, "the first outcomes trial," he said.

Based on the findings, he and others wonder if the drug is worth keeping around.

The drug did not seem to make people healthier, Curfman said. "Some people were actually made worse," he said. "All this taken together results in an unfavorable risk-benefit profile and, based on that, we don't see a rationale for keeping this on the market."

Also, he said, "the efficacy of producing weight loss with the drug is very unimpressive. In this trial, patients lost on average less than 4 kilograms [about 9 pounds] and we know that that's not going to translate into a real health benefit over time. It's not enough weight loss. The FDA has a benchmark of about 5 percent loss of baseline body weight to consider a weight loss drug [effective]."

A University of Rochester expert concurs.

"I have never really found that people taking Meridia had obtained a real substantive weight loss," said Dr. J. Chad Teeters, assistant professor of clinical medicine, cardiology division at the University of Rochester Medical Center. "It seems that a lot of these 'quick fix' weight loss drugs don't really live up to the hype and they come with risks. I think there's probably going to be a significant downturn in the use of the drug given the low efficacy and increased risk of side effects."

This trial involved almost 11,000 older overweight or obese adults with type 2 diabetes or heart disease or both who were randomized either to take Meridia or a placebo and followed for about 3.4 years.

In the group taking Meridia, 11.4 percent had a heart attack, stroke or died as the result of a heart problem, versus 10 percent in the control group, a 16 percent increase.

People taking Meridia also had a 28 percent higher risk for nonfatal heart attack and a 36 percent raised risk for nonfatal stroke, compared to those taking placebo, the authors found.

All trial participants were also engaged in a diet-and-exercise program to lose weight, whether they were taking the drug or not, said study author James. "Meridia is not a wonder drug that guarantees people lose weight but it is a major additional help for people who change their diet and increase their physical activity," he said.

But Teeters narrowed the prescription. "Good old-fashioned diet and exercise is the only substantive sustained therapy that's shown to be helpful," he said. "There's no quick-fix pill."

More information

There's more on Meridia at the U.S. National Library of Medicine.

SOURCES: Philip T. James, M.D., D.Sc., professor, London School of Hygiene and Tropical Medicine, U.K.; Chad Teeters, M.D., assistant professor, clinical medicine, cardiology division, University of Rochester Medical Center; Greg Curfman, M.D., executive editor, Sept. 2, 2010, New England Journal of Medicine

Last Updated: Sept. 01, 2010

(HealthDay News) -- A corneal abrasion occurs when the eye's cornea -- which protects the eye and helps focus light -- is scratched.

(HealthDay News) -- Drinking and driving is not only against the law, but it's a major threat to your health -- and that of others on the road.

WEDNESDAY, Sept. 1 (HealthDay News) -- A new California survey suggests that Hispanic middle-school students are more likely to smoke, drink and use marijuana than other kids their age, while Asians are the least likely to experiment with these...

WEDNESDAY, Sept. 1 (HealthDay News) -- Teens who sleep less than eight hours a night are more likely to eat a high-fat diet that puts them at risk for obesity and the many health problems connected with it, new research shows.

Here are some of the latest health and medical news developments, compiled by the editors of HealthDay: